Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 3
2020 3
2021 2
2022 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S. Ueda T, et al. Nat Biomed Eng. 2023 Jan;7(1):24-37. doi: 10.1038/s41551-022-00969-0. Epub 2022 Dec 12. Nat Biomed Eng. 2023. PMID: 36509913 Free PMC article.
Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors.
Ueda T, Kaneko S. Ueda T, et al. Int J Hematol. 2021 Nov;114(5):572-579. doi: 10.1007/s12185-020-02951-5. Epub 2020 Jul 23. Int J Hematol. 2021. PMID: 32705572 Review.
The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control …
The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, i …
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Iyoda S, Yoshida K, Shoji K, Ito N, Tanaka M, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Moritake H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H. Iyoda S, et al. Leukemia. 2024 Jul;38(7):1609-1612. doi: 10.1038/s41375-024-02244-4. Epub 2024 Apr 18. Leukemia. 2024. PMID: 38632314 No abstract available.
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1).
Ri M, Iida S, Maruyama D, Sakabe A, Kamei R, Nakashima T, Tohkin M, Osaga S, Tobinai K, Fukuhara N, Miyazaki K, Tsukamoto N, Tsujimura H, Yoshimitsu M, Miyamoto K, Tsukasaki K, Nagai H. Ri M, et al. Cancer Sci. 2021 Dec;112(12):5011-5019. doi: 10.1111/cas.15158. Epub 2021 Oct 26. Cancer Sci. 2021. PMID: 34626515 Free PMC article. Clinical Trial.
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K. Hayakawa D, et al. Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22. Thorac Cancer. 2020. PMID: 31758670 Free PMC article.